Please use this identifier to cite or link to this item: https://hdl.handle.net/10419/256567 
Year of Publication: 
2019
Series/Report no.: 
SWP Comment No. 25/2019
Publisher: 
Stiftung Wissenschaft und Politik (SWP), Berlin
Abstract: 
When talking about health risks in developing countries, many people think of events such as the Ebola virus epidemic in 2014 and 2015 in West Africa. The effects of trade in falsified and substandard medicines are far less known. Developing countries are particularly affected since they are easy targets for the illegal trade due to insufficient regulations and controls as well as limited access to health care. The health and (socio-)economic consequences are severe. Moreover, criminal net­works make large profits, usually without having to fear any significant punishment. The German government can push for a stronger focus on the issue at the World Health Assembly in May 2019. Germany's bilateral engagement should, above all, support developing countries in making drug supply chains safer.
Persistent Identifier of the first edition: 
Document Type: 
Research Report

Files in This Item:
File
Size
1.36 MB





Items in EconStor are protected by copyright, with all rights reserved, unless otherwise indicated.